An update on TroVax for the treatment of progressive castration-resistant prostate cancer.

Abstract

Prostate cancer is a common human malignancy with few effective therapeutic options for treating advanced castration-resistant disease. The potential therapeutic effectiveness of immunotherapy and vaccines, in particular, has gained popularity based on the identification of prostate-associated antigens, potent expression vectors for vaccination, and data from recent clinical trials. A modified vaccinia Ankara (MVA) virus expressing 5T4, a tumor-associated glycoprotein, has shown promise in preclinical studies and clinical trials in patients with colorectal and renal cell carcinoma. This review will discuss the rationale for immunotherapy in prostate cancer and describe preclinical and limited clinical data in prostate cancer for the MVA-5T4 (TroVax(®)) vaccine.

• Authors: Michael Abern, Howard L Kaufman, Kalyan Latchamsetty
• Journal: OncoTargets and therapy (Onco Targets Ther) Vol. 4 Pg. 33-41 ( 2011) ISSN: 1178-6930 [Electronic] New Zealand
• PMID: 21691576 (Publication Type: Journal Article)